Onkourologiya

Aims & Scope

The main objective of the journal "Cancer urology" is publishing up-to-date information about scientific clinical researches, diagnostics, treatment of oncologic urological diseases.

The aim of the edition is to inform the experts on oncologic urology about achievements in this area, to build understanding of the necessary integrated interdisciplinary approach in therapy, alongside with urologists, combining efforts of doctors of various specialties (cardiologists, pediatricians, chemotherapeutists et al.), to contribute to raising the effectiveness of oncologic patients’ treatment.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	0.1
2024	0.10

SJR (SCImago Journal Rank)

Year	Value
2024	0.116

Quartile

Year	Value
2024	Q4

h-index

Year	Value
2024	7

Journal Rank

Year	Value
2024	27795

Journal Citation Indicator

Year	Value
2024	39

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

---

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Statistics of malignant tumors of urinary and male urogenital organs in Russia and the countries of the former USSR

  Citation: 42

  Authors: E. M., V. Ð’.

• Modern approaches to kidney cancer immunotherapy

  Citation: 14

  Authors: N. E., M. V., A. A., E. S., Z. G., V. B.

• Surgical treatment of Renal Cell Carcinoma (RCC) with level III–IV tumor venous thrombosis

  Citation: 10

  Authors: M. I., V. B., M. I., P. I., K. P., I. V., S. V., O. V., K. M., V. A., E. V.

• The first experience of transperineal prostate biopsy without antibiotic prophylaxis

  Citation: 9

  Authors: D. Yu., S. V., I. N., A. V., V. A.

• The prognostic value of tumor PD-L1 status in patients with metastatic prostate cancer

  Citation: 9

  Authors: V. B., A. A., V. M., N. V., O. A., B. Sh., L. N.

• Surgical treatment of kidney cancer with extended inferior vena cava thrombosis: complications and long-term results

  Citation: 8

  Authors: V. A., Z. V., A. A., V. A., D. S., P. I., G. I., S. A.

• Soluble forms of the immune check-point receptor PD-1 and its ligand PD-L1 in blood serum of patients with renal cell carcinoma: clinical and pathologic correlations

  Citation: 8

  Authors: N. E., E. S., I. O., A. A., A. A., S. D., I. A., V. V., V. B.

• Surgical treatment of renal cell carcinoma with advanced tumor invasion of the inferior vena cava

  Citation: 8

  Authors: M. I., V. B., M. I., A. K., P. I., K. P., I. V., S. V., O. V., E. V., M. G., V. A., A. V.

• Molecular genetic diagnostics of clear cell renal cell carcinoma

  Citation: 8

  Authors: N. V., M. V., A. A., P. V., A. S., B. Sh., V. B., A. V.

• Methylation of 10 miRNA genes in clear cell renal cell carcinoma and their diagnostic value

  Citation: 7

  Authors: V. I., E. V., T. R., E. A., A. V.

---